HUE048293T2 - Eljárások hepatikus enkefalopátia kezelésére - Google Patents
Eljárások hepatikus enkefalopátia kezeléséreInfo
- Publication number
- HUE048293T2 HUE048293T2 HUE09818544A HUE09818544A HUE048293T2 HU E048293 T2 HUE048293 T2 HU E048293T2 HU E09818544 A HUE09818544 A HU E09818544A HU E09818544 A HUE09818544 A HU E09818544A HU E048293 T2 HUE048293 T2 HU E048293T2
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- hepatic encephalopathy
- treating hepatic
- treating
- encephalopathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10234908P | 2008-10-02 | 2008-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE048293T2 true HUE048293T2 (hu) | 2020-07-28 |
Family
ID=42073897
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09818544A HUE048293T2 (hu) | 2008-10-02 | 2009-10-02 | Eljárások hepatikus enkefalopátia kezelésére |
HUE19207534A HUE065491T2 (hu) | 2008-10-02 | 2009-10-02 | A hepatikus enkefalopátia kezelése rifaximin alkalmazásával |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE19207534A HUE065491T2 (hu) | 2008-10-02 | 2009-10-02 | A hepatikus enkefalopátia kezelése rifaximin alkalmazásával |
Country Status (20)
Country | Link |
---|---|
US (11) | US20100204173A1 (hu) |
EP (3) | EP2350096B1 (hu) |
JP (2) | JP6037615B2 (hu) |
CN (1) | CN102245615A (hu) |
AU (1) | AU2009298389C1 (hu) |
BR (1) | BRPI0920465A2 (hu) |
CA (1) | CA2739436C (hu) |
CY (1) | CY1122806T1 (hu) |
DK (2) | DK2350096T3 (hu) |
ES (2) | ES2972135T3 (hu) |
FI (1) | FI3628319T3 (hu) |
HR (2) | HRP20240317T1 (hu) |
HU (2) | HUE048293T2 (hu) |
IL (1) | IL212055A0 (hu) |
LT (2) | LT3628319T (hu) |
MX (2) | MX364102B (hu) |
PL (2) | PL3628319T3 (hu) |
PT (2) | PT3628319T (hu) |
SI (2) | SI2350096T1 (hu) |
WO (1) | WO2010040020A1 (hu) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
WO2010040020A1 (en) * | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
KR20120025578A (ko) * | 2009-06-02 | 2012-03-15 | 샐릭스 파마슈티컬스 리미티드 | 간성 뇌병증의 치료방법 |
NZ597080A (en) * | 2009-06-15 | 2014-02-28 | Salix Pharmaceuticals Ltd | Modulation of systemic exposure to rifaximin |
CA2778181C (en) | 2009-10-26 | 2024-05-28 | Thomas Julius Borody | Therapy for enteric infections |
RU2013109251A (ru) | 2010-08-04 | 2014-09-10 | Томас Джулиус БОРОДИ | Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки |
WO2012076832A1 (en) * | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
CN103561752B (zh) | 2011-03-09 | 2016-04-20 | 明尼苏达大学评议会 | 用于移植结肠微生物群的组合物和方法 |
US20130184302A1 (en) | 2011-11-02 | 2013-07-18 | Enoch Bortey | Methods for treating irritable bowel syndrome (ibs) and infections |
US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
ITBO20120368A1 (it) * | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014043433A1 (en) * | 2012-09-13 | 2014-03-20 | Salix Pharmaceuticals, Ltd | Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US20150335615A1 (en) * | 2013-01-04 | 2015-11-26 | Toshihisa Kawai | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US20160089363A1 (en) * | 2013-04-30 | 2016-03-31 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
CN103340856A (zh) * | 2013-07-09 | 2013-10-09 | 荣港生技医药科技(北京)有限公司 | 一种利福昔明药物组合物及其制备方法 |
WO2015114308A1 (en) | 2014-01-29 | 2015-08-06 | Umecrine Cognition Ab | Steroid compound for use in the treatment of hepatic encephalopathy |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
NZ723571A (en) | 2014-05-12 | 2020-02-28 | Alfasigma Spa | New solvated crystal form of rifaximin, production, compositions and uses thereof |
WO2016003536A1 (en) * | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
AR103384A1 (es) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA |
WO2016183577A1 (en) | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
BR112017024777A2 (pt) | 2015-05-22 | 2018-08-07 | Univ Arizona State | uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados? |
KR20180100660A (ko) * | 2016-01-08 | 2018-09-11 | 코로나리콘셉츠 엘엘씨 | 간성 뇌증의 치료를 위한 치료제의 식품 기반 전달 |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
EP3518924B1 (en) * | 2016-09-30 | 2022-08-10 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
CN106822125A (zh) * | 2017-02-28 | 2017-06-13 | 丹诺医药(苏州)有限公司 | 一种利福霉素‑喹嗪酮双靶标分子的新用途 |
CN106822119A (zh) * | 2017-02-28 | 2017-06-13 | 丹诺医药(苏州)有限公司 | 一种利福霉素‑硝基咪唑偶联分子的新用途 |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
AU2018250206A1 (en) | 2017-04-05 | 2019-10-31 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (PD) and related disorders |
CN110996917A (zh) | 2017-05-26 | 2020-04-10 | 克雷斯顿沃控股公司 | 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法 |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
WO2019092614A1 (en) | 2017-11-10 | 2019-05-16 | Cosmo Technologies Ltd. | Oral rifamycin sv compositions |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
AU2019351017A1 (en) | 2018-09-27 | 2021-04-29 | Finch Therapeutics Holdings Llc. | Compositions and methods for treating epilepsy and related disorders |
CN113966229A (zh) | 2019-05-10 | 2022-01-21 | 爱沐疗法公司 | 用于改善花生过敏患者的生活质量的方法 |
KR20230005161A (ko) * | 2020-03-24 | 2023-01-09 | 보슈 헬스 아일랜드 리미티드 | 현성 간성 뇌병증의 치료를 위한 리팍시민의 고체 분산물 |
WO2023225073A1 (en) * | 2022-05-18 | 2023-11-23 | Virginia Commonwealth University | Methods for treatment of cognitive impairment in cirrhosis patients |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3132910A (en) | 1962-03-26 | 1964-05-12 | Eastman Kodak Co | Cabinetry structure |
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
US4343785A (en) | 1981-08-10 | 1982-08-10 | Basf Wyandotte Corporation | Gel dentifrice compositions |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
US6562629B1 (en) * | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
ES2114502B1 (es) | 1996-07-29 | 1999-07-01 | Univ Santiago Compostela | Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas. |
AU4414497A (en) | 1996-09-13 | 1998-04-02 | University Technology Corporation | Biocompatible cationic detergents and uses therefor |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
US20020028764A1 (en) | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
AU2003268330A1 (en) * | 2002-08-29 | 2004-03-19 | Activbiotics, Inc. | Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
TW200418485A (en) * | 2002-09-23 | 2004-10-01 | Activbiotics Inc | Rifalazil compositions and therapeutic regimens |
ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7256202B2 (en) | 2003-12-31 | 2007-08-14 | Halow George M | Composition and method for treatment of hepatic encephalopathy |
EP2319581B1 (en) | 2004-11-26 | 2015-02-25 | UCL Business PLC | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
US20090233888A1 (en) | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
US8987292B2 (en) | 2006-03-09 | 2015-03-24 | Salix Pharmaceuticals, Ltd. | Rifaximin anti-rectal dysfunction preparation |
US20080020032A1 (en) | 2006-07-21 | 2008-01-24 | Michael Crowley | Hydrophobic abuse deterrent delivery system for hydromorphone |
DK2054066T3 (en) | 2006-08-02 | 2015-06-08 | Salix Pharmaceuticals Inc | METHODS OF TREATMENT OF RADIATE ENTERITIS |
CN101534840A (zh) | 2006-08-02 | 2009-09-16 | 萨利克斯药品公司 | 治疗放射性肠炎的方法 |
US8633234B2 (en) | 2006-09-22 | 2014-01-21 | Cipla Limited | Rifaximin |
WO2008085484A2 (en) | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
EP3714878B1 (en) | 2007-07-06 | 2022-01-19 | Lupin Limited | Pharmaceutical compositions of rifaximin |
WO2009008005A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
CA2716830C (en) | 2008-02-25 | 2019-01-08 | Salix Pharmaceuticals, Ltd. | Forms of rifaximin and uses thereof |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
NZ587098A (en) | 2008-02-26 | 2012-09-28 | Salix Pharmaceuticals Ltd | Use of a rifamycin class antibiotic for treating diarrhea-associated Irritable Bowel Syndrome and hepatic encephalopathy |
US20100317681A1 (en) | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
WO2010040020A1 (en) * | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
KR20120025578A (ko) * | 2009-06-02 | 2012-03-15 | 샐릭스 파마슈티컬스 리미티드 | 간성 뇌병증의 치료방법 |
DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
ES2655115T3 (es) | 2010-08-26 | 2018-02-16 | Boehringer Ingelheim International Gmbh | Procedimientos de administración de un inhibidor de EGFR |
KR20130027255A (ko) * | 2011-09-07 | 2013-03-15 | 삼성전자주식회사 | 키 조립체 및 이를 구비한 회전식 입력 장치 |
DK2785349T4 (da) | 2011-11-30 | 2023-01-09 | Astrazeneca Ab | Kombinationsbehandling af cancer |
CN106462181B (zh) | 2014-04-29 | 2019-10-25 | 惠普发展公司,有限责任合伙企业 | 用于计算装置的铰接组件 |
US20160191956A1 (en) * | 2014-12-15 | 2016-06-30 | Cable Television Laboratories, Inc. | Software defined networking in a cable tv system |
RS59672B1 (sr) | 2015-06-04 | 2020-01-31 | Pfizer | Čvrsti dozni oblici palbocikliba |
-
2009
- 2009-10-02 WO PCT/US2009/059321 patent/WO2010040020A1/en active Application Filing
- 2009-10-02 LT LTEP19207534.9T patent/LT3628319T/lt unknown
- 2009-10-02 SI SI200932045T patent/SI2350096T1/sl unknown
- 2009-10-02 PL PL19207534.9T patent/PL3628319T3/pl unknown
- 2009-10-02 BR BRPI0920465-2A patent/BRPI0920465A2/pt not_active Application Discontinuation
- 2009-10-02 DK DK09818544.0T patent/DK2350096T3/da active
- 2009-10-02 MX MX2014013652A patent/MX364102B/es unknown
- 2009-10-02 US US12/572,344 patent/US20100204173A1/en not_active Abandoned
- 2009-10-02 PL PL09818544T patent/PL2350096T3/pl unknown
- 2009-10-02 LT LTEP09818544.0T patent/LT2350096T/lt unknown
- 2009-10-02 SI SI200932192T patent/SI3628319T1/sl unknown
- 2009-10-02 CN CN2009801490791A patent/CN102245615A/zh active Pending
- 2009-10-02 HU HUE09818544A patent/HUE048293T2/hu unknown
- 2009-10-02 HU HUE19207534A patent/HUE065491T2/hu unknown
- 2009-10-02 EP EP09818544.0A patent/EP2350096B1/en active Active
- 2009-10-02 FI FIEP19207534.9T patent/FI3628319T3/fi active
- 2009-10-02 JP JP2011530261A patent/JP6037615B2/ja active Active
- 2009-10-02 EP EP19207534.9A patent/EP3628319B1/en active Active
- 2009-10-02 CA CA2739436A patent/CA2739436C/en active Active
- 2009-10-02 ES ES19207534T patent/ES2972135T3/es active Active
- 2009-10-02 ES ES09818544T patent/ES2770308T3/es active Active
- 2009-10-02 PT PT192075349T patent/PT3628319T/pt unknown
- 2009-10-02 DK DK19207534.9T patent/DK3628319T3/da active
- 2009-10-02 EP EP24155114.2A patent/EP4342465A3/en active Pending
- 2009-10-02 MX MX2011003548A patent/MX2011003548A/es active IP Right Grant
- 2009-10-02 AU AU2009298389A patent/AU2009298389C1/en active Active
- 2009-10-02 HR HRP20240317TT patent/HRP20240317T1/hr unknown
- 2009-10-02 PT PT98185440T patent/PT2350096T/pt unknown
-
2011
- 2011-03-31 IL IL212055A patent/IL212055A0/en active IP Right Grant
- 2011-03-31 US US13/077,373 patent/US20110243879A1/en not_active Abandoned
-
2013
- 2013-02-15 US US13/768,617 patent/US8969398B2/en active Active
-
2015
- 2015-02-03 US US14/612,697 patent/US9629829B2/en active Active
- 2015-05-21 JP JP2015103724A patent/JP2015166381A/ja active Pending
-
2017
- 2017-03-16 US US15/460,704 patent/US9949958B2/en active Active
-
2018
- 2018-03-15 US US15/922,010 patent/US10335397B2/en active Active
-
2019
- 2019-05-16 US US16/414,018 patent/US10709694B2/en active Active
-
2020
- 2020-02-19 HR HRP20200284TT patent/HRP20200284T1/hr unknown
- 2020-02-21 CY CY20201100167T patent/CY1122806T1/el unknown
- 2020-06-05 US US16/893,651 patent/US20200368213A1/en not_active Abandoned
-
2021
- 2021-03-26 US US17/213,678 patent/US11633384B2/en active Active
-
2023
- 2023-03-06 US US18/117,899 patent/US20240066010A1/en active Pending
- 2023-04-18 US US18/135,823 patent/US20230330071A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL212055A0 (en) | Methods of treating hepatic encephalopathy | |
HK1255283A1 (zh) | 用於治療流感的化合物和方法 | |
IL207752A0 (en) | Methods of treating inflammation | |
IL208354A0 (en) | Methods of treatment | |
GB2471987B (en) | Anti-tumoural effects of cannabinoid combinations | |
IL211061A0 (en) | Methods of treating thalassemia | |
EP2331564A4 (en) | PROCESS FOR TREATMENT OF IGNITION | |
GB2478072B (en) | Anti-tumoural effects of cannabinoid combinations | |
EP2437603A4 (en) | METHODS OF TREATING HEPATIC ENCEPHALOPATHY | |
GB201107850D0 (en) | Anti-tumoural effects of cannabinoid combinations | |
ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
IL210097B (en) | Compounds and methods for the treatment of influenza | |
EP2461806A4 (en) | SMALL ANTI-ANGIOGENIC MOLECULES AND METHODS OF USE | |
HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
EP2249765A4 (en) | DAPSONE TO TREAT THE ROSACEA | |
EP2300496A4 (en) | ATHEROSCLEROSIS TREATMENT METHODS | |
EP2306838A4 (en) | METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS | |
GB2462856B (en) | Shower assemblies | |
ZA201006046B (en) | Methods of treating inflammation | |
PL386302A1 (pl) | Nowa pochodna izotiazolopirydyny | |
GB0816865D0 (en) | Enabling monitoring of components | |
GB0804468D0 (en) | Treatment of influenza | |
HU0800656D0 (en) | Effective use of tea-composition | |
GB0821710D0 (en) | Derivatives of dihydroindolone |